US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

 
• By Derrick Gingery

The number of standard and priority reviews also decreased significantly in FY 2023 compared to the previous year, which caused the fee for redeeming a voucher to rise.

increasing costs
The FDA's cost to review NME NDAs and BLAs in FY 2023 was the second-highest total since FY 2009. • Source: Shutterstock

More from User Fees

More from Pathways & Standards